Blocking MAPK signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses

Journal of Investigative Dermatology

Volumn 131, Issue 9, 2011, Pages 1927-1935

  Miyagaki, Tomomitsu ^a,b   Sugaya, Makoto ^a,b   Okochi, Hitoshi ^b   Asano, Yoshihide ^a   Tada, Yayoi ^a   Kadono, Takafumi ^a   Blauvelt, Andrew ^c,d   Tamaki, Kunihiko ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 3 INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 42; MITOGEN ACTIVATED PROTEIN KINASE 44; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOSTATIN M; PODOPLANIN; PROTEIN PROX 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; UO 126; VASCULOTROPIN RECEPTOR 3;

ANTIGEN EXPRESSION; ARTICLE; CELL MIGRATION; COMPARATIVE STUDY; CONTACT HYPERSENSITIVITY RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 80051790434     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.135     Document Type: Article

References (45)

1. Adjei AA, Cohen RB, Franklin W et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-46
2. Beckstead JH, Wood GS, Fletcher V (1985) Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol 119:294-300 (Pubitemid 15040428)
3. Cardones AR, Leitner WW, Murakami T et al. (2006) Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native protein. Microvas Res 71:32-9 (Pubitemid 43175846)
4. Eberhard Y, Ortiz S, Ruiz Lascano A et al. (2004) Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants. BMC Immunol 5:7
5. El Mabrouk M, Sylvester J, Zafarullah M (2007) Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochem Biophys Acta 1773:309-20
6. Engeman TM, Gorbachev AV, Gladue RP et al. (2000) Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti-secondary lymphoid chemokine antibody during hapten sensitiza-tion. J Immunol 164:5207-14 (Pubitemid 30305197)
7. Fagarasan S, Shinkura R, Kamata T et al. (2000) Alymphoplasia (aly)-type nuclear factor kB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. J Exp Med 191:1477-86 (Pubitemid 30257345)
8. Forster R, Schubel A, Breitfeld D et al. (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33 (Pubitemid 29468627)
9. Gunn MD, Kyuwa S, Tam C et al. (1999) Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189:451-60 (Pubitemid 29187367)
10. Gunn MD, Tangemann K, Tam C et al. (1998) A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 95: 258-63 (Pubitemid 28103941)
11. Haura EB, Ricart AD, Larson TG et al. (2010) A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16:2450-7
12. Hong YK, Foreman K, Shin JW et al. (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36:683-5 (Pubitemid 38886627)
13. Jackson DG (2003) The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 13:1-7 (Pubitemid 36120543)
14. Jaffee BD, Manos EJ, Collins RJ et al. (2000) Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo. Biochem Biophys Res Commun 268:647-51 (Pubitemid 30119676)
15. Kriehuber E, Breiteneder-Geleff S, Groeger M et al. (2001) Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 194:797-808 (Pubitemid 32983015)
16. Lee YJ, Heo JS, Suh HN et al. (2007) Interleukin-6 stimulates alpha-MG uptake in renal proximal tubule cells: involvement of STAT3, PI3K/Akt, MAPKs, and NF-kappaB. Am J Physiol Renal Physiol 293:1036-46
17. Leng H, Luo X, Ma L et al. (2009) Reversal of ultraviolet B-induced immunosuppression by inhibition of the extracellular signal-regulated mitogen-activated protein kinase. Photodermatol Photoimmunol Photo-med 25:264-9
18. LoRusso PM, Krishnamurthi SS, Rinehart JJ et al. (2010) Phase I pharmaco-kinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-37
19. Manzo A, Bugatti S, Caporali R et al. (2007) CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol 171:1549-62 (Pubitemid 350158316)
20. MartIn-Fontecha A, Sebastiani S, Höpken UE et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198:615-21 (Pubitemid 37040395)
21. Miles SA, Martinez-Maza O, Rezai A et al. (1992) Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255:1432-4
22. Modur V, Feldhaus MJ, Weyrich AS et al. (1997) Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100:158-68 (Pubitemid 27311254)
23. Murakami-Mori K, Taga T, Kishimoto T et al. (1995) AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor: complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J Clin Invest 96:1319-27
24. Nair BC, DeVico AL, Nakamura S et al. (1992) Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 255:1430-2
25. Nakano H, Lin KL, Yanagita M et al. (2009) Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol 10:394-402
26. Nakano H, Mori S, Yonekawa H et al. (1998) A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 91:2886-95 (Pubitemid 28227539)
27. Ohl L, Mohaupt M, Czeloth N et al. (2004) CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21:279-88 (Pubitemid 39094056)
28. Pelletier JP, Martel-Pelletier J (2003) Oncostatin M: foe or friend? Arthritis Rheum 48:3301-3 (Pubitemid 37531895)
29. Podgrabinska S, Braun P, Velasco P et al. (2002) Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 99:16069-74 (Pubitemid 35462750)
30. Saeki H, Moore AM, Brown MJ et al. (1999) Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 162:2472-5 (Pubitemid 29309263)
31. Schneider MA, Meingassner JG, Lipp M et al. (2007) CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 204:735-45 (Pubitemid 46631604)
32. Serra HM, Eberhard Y, Martín AP et al. (2004) Secondary lymphoid tissue chemokine (CCL21) is upregulated in allergic contact dermatitis. Int Arch Allergy Immunol 133:64-71 (Pubitemid 38199401)
33. Sheng KC, Pietersz GA, Wright MD et al. (2005) Dendritic cells: activation and maturation-applications for cancer immunotherapy. Curr Med Chem 12:1783-800 (Pubitemid 40895000)
34. Stancato LF, Sakatsume M, David M et al. (1997) Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 17:3833-40 (Pubitemid 27281858)
35. Suda T, Chida K, Todate A et al. (2003) Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine 17:335-40
36. Sugaya M, Fang L, Cardones AR et al. (2006) Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 177:7665-72 (Pubitemid 44846281)
37. Tanaka M, Miyajima A (2003) Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149:39-52
38. Thiel MJ, Schaefer CJ, Lesch ME et al. (2007) Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 56:3347-57 (Pubitemid 47585429)
39. Thoma B, Bird TA, Friend DJ et al. (1994) Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269:6215-22 (Pubitemid 24243012)
40. Turnquist HR, Lin X, Ashour AE et al. (2007) CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncology 30:631-9
41. Wang JY, Wilcoxen KM, Nomoto K et al. (2007) Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 7:1364-78 (Pubitemid 47471235)
42. Watanabe R, Fujimoto M, Ishiura N et al. (2007) CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol 171:560-70 (Pubitemid 47344688)
43. Wong KK (2009) Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 4:28-35
44. Yousefieh N, Hahto SM, Stephens AL et al. (2009) Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2:59-67
45. Zhang Q, Putheti P, Zhou Q et al. (2008) Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev 19:347-56